Every Form 4 that Shattuck Labs, Inc. (STTK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow STTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STTK filings page.
Shattuck Labs Chief Technical Officer Abhinav A. Shukla reported option exercises and a small share sale in Common Stock. He exercised options to acquire 12,563 shares at $3.57 per share in two transactions and now holds 98,533 Common shares directly.
Shukla also sold 410 shares of Common Stock at a weighted average price of $7.01 per share, with individual sale prices ranging from $7.00 to $7.03. The sale was made under a pre-arranged Rule 10b5-1 trading plan designed to fund option exercise costs and related tax withholding. Following these transactions, he also holds 14,140 stock options with a $3.57 exercise price, expiring on January 25, 2033.
Shattuck Labs Chief Technical Officer Abhinav A. Shukla reported option-related trades in the company’s common stock. On June 30 and July 1, he exercised stock options covering a total of 23,465 shares at an exercise price of $3.57 per share.
The same total of 23,465 shares of common stock was sold in open-market transactions at weighted average prices of about $7.08 and $7.07 per share, under a pre-arranged Rule 10b5-1 trading plan intended to fund the option exercise price and estimated tax withholding. After these transactions, he directly holds 86,380 shares of common stock and continues to hold unexercised portions of an option covering up to 52,200 shares that vests through January 25, 2027.
Shattuck Labs, Inc. Chief Medical Officer Arundathy N. Pandite reported an open-market sale of 30,000 shares of common stock at a weighted average price of $7.01 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026.
Following this sale, Pandite continues to hold 136,219 shares of Shattuck Labs common stock directly.
Shattuck Labs director-associated funds increased their indirect stake through derivative securities. Entities affiliated with OrbiMed bought a total of 1,250,000 Pre-Funded Warrants for Shattuck Labs common stock on June 11, 2026, each with an exercise price of $0.0001 per share.
Following these purchases, one OrbiMed vehicle held 5,303,908 Pre-Funded Warrants and 1,051,021 common shares indirectly, while another held 26,519,541 Pre-Funded Warrants and 5,255,106 common shares indirectly. The warrants are exercisable after issuance, subject to a 9.99% beneficial ownership blocker.
Shattuck Labs, Inc. reported that investment entities affiliated with OrbiMed purchased pre-funded warrants linked to its June 2026 public offering. OrbiMed-related funds acquired pre-funded warrants exercisable for a total of 1,250,000 shares of common stock at an exercise price of $0.0001 per share, subject to a 9.99% beneficial ownership blocker. The public offering comprised 10,879,376 common shares at $4.00 per share and, in lieu of shares to certain investors, 7,870,624 pre-funded warrants at $3.9999 each. The securities are held of record by OrbiMed Private Investments IX, LP and OrbiMed Genesis Master Fund, L.P., while OrbiMed Advisors and its affiliated general partners may be deemed to share voting and investment power but disclaim beneficial ownership beyond their pecuniary interests.
Shattuck Labs director Clay B. Siegall bought 62,500 shares of the company’s common stock in an open-market transaction at $4.00 per share. After this purchase, he directly owns 318,608 shares. The footnote explains the shares were purchased in connection with the company’s underwritten offering that closed on June 11, 2026.
Shattuck Labs, Inc. reported that entities affiliated with OrbiMed converted previously issued warrants into new pre-funded warrants and updated their indirect holdings of common stock. On June 8, 2026, OrbiMed-related funds converted common warrants exercisable for 3,073,298 and 15,366,490 shares of common stock into an equal number of pre-funded warrants, with the common warrants carrying an exercise price of $1.0846 per share and the new pre-funded warrants carrying an exercise price of $0.0001 per share. These securities stem from an August 2025 private placement where OrbiMed-affiliated investors purchased 6,306,127 common shares, pre-funded warrants for up to 12,133,661 shares, and accompanying common warrants for up to 18,439,799 shares. All positions are held indirectly through OrbiMed-managed investment funds, and the OrbiMed entities disclaim beneficial ownership beyond any pecuniary interest.
Shattuck Labs director affiliate restructures warrant holdings in STTK. Investment entities associated with OrbiMed converted common warrants into pre-funded warrants linked to Shattuck Labs common stock. Four derivative transactions converted an aggregate of 3,073,298 and 15,366,490 common warrants into corresponding pre-funded warrants at an exercise price of $0.0001 per share.
The common warrants, originally struck at $1.0846 per share, were exchanged on June 8, 2026, leaving no common warrants reported as remaining. The pre-funded warrants are exercisable at any time, subject to a 9.99% beneficial ownership blocker, and will expire once fully exercised. All positions are held indirectly through OrbiMed-managed funds, and the reporting persons and related OrbiMed entities expressly disclaim beneficial ownership beyond any pecuniary interest.
Shattuck Labs, Inc. reported that director Daniel G. Baker received a grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on May 29, 2036.
The award vests in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, as long as Baker continues to serve the company. After this grant, he holds options on 81,000 shares directly.
Shattuck Labs, Inc. director George Golumbeski received a compensation-related grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on May 29, 2036. They vest in full on the earlier of the one-year anniversary of the May 29, 2026 grant date or immediately before the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, he holds 81,000 stock options directly.
Shattuck Labs, Inc. director Neil W. Gibson received a grant of stock options covering 81,000 shares of common stock. These options have an exercise price of $5.95 per share and expire on May 29, 2036.
The option grant vests in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, as long as Gibson continues to serve the company. Following this grant, he holds options for 81,000 shares directly.
Shattuck Labs director Ashiya Mona received a grant of stock options covering 81,000 shares of common stock. These options have an exercise price of $5.95 per share and expire on May 29, 2036. They vest in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual stockholder meeting, contingent on continued service.
Under an agreement with OrbiMed entities, any securities or economic benefits from these options must be transferred so they ultimately accrue to OrbiMed Private Investments IX, LP. This is a compensation-related award, not an open-market purchase or sale.
Shattuck Labs, Inc. director Clay B. Siegall received a grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on May 29, 2036. They vest in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual stockholder meeting, as long as he continues serving the company. This is a compensation-related award, not an open-market purchase or sale, and results in 81,000 derivative securities held after the transaction.
Shattuck Labs director Helen M. Boudreau received a grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and give her the right to buy the shares in the future.
According to the terms, the 81,000 options will vest in full on the earlier of the one-year anniversary of the May 29, 2026 grant date or immediately before Shattuck Labs’ next annual meeting of stockholders, subject to her continued service. Following this grant, she holds 81,000 derivative securities directly.
Shattuck Labs director Clay B. Siegall increased his direct stake by exercising warrants for common stock. On May 22, 2026, he acquired 128,054 shares of common stock at an exercise price of $1.0846 per share through the exercise of warrants.
These warrants were originally issued in a private placement under an August 4, 2025 securities purchase agreement, where he bought 128,054 shares of common stock with accompanying warrants at a combined price of $0.8677 per share and warrant. Following the latest transactions, Siegall directly holds 256,108 common shares, with the exercised warrants position reduced to zero.
Shattuck Labs, Inc. Chief Technical Officer Abhinav A. Shukla reported routine equity transactions involving company stock. He received a grant or award of 5,122 shares of common stock at $1.0846 per share, increasing his direct holdings to 86,380 shares.
On the same date, he exercised warrants covering 5,122 shares of common stock at an exercise price of $1.0846 per share, eliminating this warrant position. Footnotes explain these warrants and shares stemmed from a prior private placement that included common stock and accompanying warrants issued under a securities purchase agreement.
Shattuck Labs, Inc. officer Stephen Stout reported acquiring additional equity through a private placement-related transaction. He acquired 12,805 shares of common stock and exercised accompanying warrants for 12,805 shares at an exercise price of $1.0846 per share, bringing his direct holdings to 93,366 common shares. These securities stem from a prior securities purchase agreement where common stock and warrants were originally issued together at a combined price of $0.8677 per share and warrant, with the warrants exercisable during a period tied to clinical data milestones for SL-325.
Shattuck Labs, Inc. Chief Financial Officer Andrew R. Neill reported an exercise of warrants and related share acquisition. He acquired 64,027 shares of common stock, linked to a warrant exercise covering 64,027 underlying shares at an exercise price of $1.0846 per share. Following these transactions, he directly owns 292,251 shares of common stock. No sales or dispositions were reported in this filing, and no derivative warrants remain outstanding from this grant.
Shattuck Labs Chief Technical Officer Abhinav A. Shukla reported an option exercise and related share sale. He exercised stock options for 2,032 shares of common stock at an exercise price of $3.57 per share and sold 2,032 shares in an open-market transaction at a weighted average price of $7.01 per share.
The transactions were carried out under a Rule 10b5-1 trading plan adopted on February 2, 2026, designed to sell shares received from option exercises only as needed to fund exercise costs and estimated tax withholding. Following these transactions, he directly holds 81,258 shares of common stock and 50,168 stock options.
Shattuck Labs, Inc. chief medical officer Arundathy N. Pandite reported an open-market sale of 30,000 shares of common stock. The shares were sold at a weighted average price of $6.61 per share, in multiple trades between $6.41 and $7.03. Following the transaction, she directly holds 166,219 shares. The sale was effected under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026.
Shattuck Labs, Inc. director and Chief Executive Officer Taylor Schreiber reported acquiring 25,610 shares of common stock through the exercise of warrants at a conversion price of $1.0846 per share. Following these transactions, Schreiber holds 122,222 shares directly and 2,610,750 shares indirectly through Houghton Capital Holdings, LLC.
Shattuck Labs, Inc. executive Stephen Stout reported a small tax-related share disposition. On this Form 4, 968 shares of Common Stock were withheld at $6.85 per share to cover tax obligations, a non-market transaction. After this withholding, Stout directly holds 80,561 shares of Shattuck Labs common stock.
Shattuck Labs Chief Medical Officer reports share disposition
Shattuck Labs, Inc.'s Chief Medical Officer, Arundathy N. Pandite, reported a transaction in the company’s common stock. On 01/25/2026, 3,195 shares of common stock were disposed of in a transaction coded "F" at a price of $4.15 per share. Following this transaction, Pandite beneficially owns 196,219 shares of Shattuck Labs common stock in direct ownership form.
Shattuck Labs, Inc. insider transaction: Company officer Stephen Stout, who serves as General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer, reported a disposition of 593 shares of Shattuck Labs common stock on 01/25/2026 at a price of $4.15 per share. After this transaction, he beneficially owned 81,529 shares of common stock in direct ownership form.
Shattuck Labs, Inc. Chief Business Officer Casi DeYoung reported a small share disposition in company stock. On 01/25/2026, DeYoung disposed of 2,286 shares of Shattuck Labs common stock at a price of $4.15 per share in a transaction coded "F," which typically reflects a disposition reported on a Form 4. Following this transaction, DeYoung directly beneficially owned 73,480 shares of Shattuck Labs common stock.
Shattuck Labs Chief Financial Officer Andrew R. Neill reported a small change in his holdings of Shattuck Labs, Inc. common stock. On January 25, 2026, he disposed of 2,589 shares of common stock in a transaction reported under SEC transaction code "F" at a reported price of $4.15 per share. Following this transaction, Neill beneficially owns 228,224 shares of Shattuck Labs common stock, held directly.
Shattuck Labs, Inc. reported that officer Stephen Stout received a stock option award for 351,400 shares of common stock at an exercise price of $4.75 per share on January 10, 2026. The option vests over time, with one quarter vesting on January 10, 2027 and the remaining three quarters vesting in equal monthly installments through January 10, 2030, contingent on his continued service.
On the same date, 4,153 shares of common stock were withheld at $4.75 per share in a transaction coded “F,” typically used for tax withholding, leaving Stout with 82,122 common shares held directly after the transaction.
Shattuck Labs, Inc. Chief Business Officer Casi DeYoung reported an equity award and a share disposition. On January 10, 2026, DeYoung was granted a stock option to purchase 381,600 shares of common stock at an exercise price of $4.75 per share. According to the vesting terms, one quarter of the option vests on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to continued service. On the same date, 5,699 shares of common stock were disposed of at $4.75 per share, after which DeYoung directly owned 75,766 shares of common stock.
Shattuck Labs, Inc. reported an equity award to its Chief Technical Officer, Abhinav A. Shukla. On January 10, 2026, he received a stock option covering 315,500 shares of Shattuck Labs common stock at an exercise price of $4.75 per share, reported as a derivative security held directly.
The option has a long-term vesting schedule: one quarter of the shares will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, conditioned on his continued service with the company. The option expires on January 10, 2036, giving him a multi-year window to exercise once vested.
Shattuck Labs, Inc. reported an insider equity transaction by its Chief Medical Officer, Pandite Arundathy N. On January 10, 2026, she was granted an option to purchase 487,800 shares of common stock at an exercise price of $4.75 per share. The option vests over time: one quarter of the shares on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, contingent on her continued service.
On the same date, she disposed of 6,851 shares of common stock at $4.75 per share, and reported owning 199,414 common shares directly after this transaction.
Shattuck Labs, Inc. Chief Financial Officer Andrew R. Neill reported new equity compensation and a related share withholding. On January 10, 2026, he received a stock option to purchase 549,800 shares of Shattuck Labs common stock at an exercise price of $4.75 per share. According to the vesting terms, one quarter of the option will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, contingent on his continued service.
On the same date, 6,660 shares of common stock were disposed of at $4.75 per share in a transaction coded "F," which typically reflects shares withheld to cover taxes upon vesting or exercise. After this transaction, Neill directly beneficially owned 230,813 shares of common stock and 549,800 stock options.
Shattuck Labs, Inc. reported that Chief Executive Officer and director Taylor Schreiber received a new stock option grant on January 10, 2026. The option gives him the right to buy 1,548,300 shares of Shattuck Labs common stock at an exercise price of $4.75 per share and expires on January 10, 2036.
According to the vesting schedule, one quarter of the option will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, as long as he continues serving the company. After this grant, he beneficially owns 1,548,300 derivative securities directly.